ELN-DAVID recommendations for NGS-based FLT3 -ITD MRD testing for patients with acute myeloid leukemia

Blood 2026 Open access

Read full text
Authors: Christopher S. Hourigan, Lisanne Beugelink, Jad Othman, Gege Gui, Adam Ivey, Richard Dillon, Christian Thiede, Mark J. Levis, Laura W. Dillon, Andrew H Wei, Ing Soo Tiong, Sun Loo
+9 more Konstanze Döhner, Isabell Arnhardt, Artur Kowalik, Nicola Potter, D H Kim, Claude Preudhomme, Nicolas Duployez, Michael Heuser, Peter JM Valk
DOI: 10.1182/blood.2026033569
Cited by: 4
References: 23

Abstract

ABSTRACT: FLT3-internal tandem duplication measurable residual disease testing for patients in remission from acute myeloid leukemia is now recommended by the recently updated clinical standard-of-care guidelines. This companion technical note provides important laboratory and clinical recommendations regarding such testing.

Fields of Study & Subjects

Acute Myeloid Leukemia Research Chronic Myeloid Leukemia Treatments Retinoids in leukemia and cellular processes

Publication details

Journal / source
Blood
Publisher
American Society of Hematology
Volume
148
Issue
7
Pages
910–913
Publication date
4 June 2026
Language
EN